ddRNAi Agent Targets HBV Genome Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for chronic hepatitis B infection have limited inhibitory effects on viral gene expression and replication, and are plagued by issues such as reversible suppression and the development of viral resistance, highlighting a need for a new therapeutic agent.
Innovation Solution
A DNA-directed RNA interference (ddRNAi) agent is developed, comprising effector sequences that target specific regions of the Hepatitis B Virus (HBV) genome, inhibiting gene expression by forming double-stranded RNA segments that anneal to complementary sequences, thereby reducing viral load and infectivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies (e.g., Lamivudine) are used to suppress HBV replication, then viral replication is inhibited, but the effect is reversible and viral resistance develops
Solution Approach 1:
The invention targets multiple distinct regions of the HBV genome simultaneously using multiple RNAi agents, each targeting a different viral gene or region. This multi-target approach prevents the virus from developing resistance through single mutations, as escape mutants would need to simultaneously mutate multiple target sites, which is statistically improbable
Solution Approach 2:
The invention changes the mechanism of action from nucleoside analog reverse transcription inhibition to RNA interference-mediated gene silencing. By using dsRNA or shRNA molecules that trigger the RNAi pathway, the therapy achieves more durable suppression of viral gene expression and replication, overcoming the reversible nature of conventional nucleoside analog therapy
2Quantity of substance
If current therapies are used to suppress HBV replication, then viral load is reduced, but viral resistance develops after 6 months
Solution Approach 1:
The invention divides the viral genome into multiple target sites and uses separate RNAi agents against each site. This segmentation of targeting strategies means that resistance would require simultaneous mutations at multiple independent target locations, dramatically reducing the probability of resistance emergence
Solution Approach 2:
The RNAi agents target multiple different viral genes (surface antigen, core antigen, polymerase, X gene) with a single therapeutic approach. This multi-functional targeting of different viral proteins simultaneously reduces overall viral load while preventing resistance through diverse target engagement
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ddRNAi agent effectively inhibits HBV gene expression, reducing viral load and the severity of symptoms, while minimizing the emergence of escape mutants, offering a more sustainable treatment option compared to existing therapies.
Implementation Method 1
forming double-stranded RNA segments that anneal to complementary sequences
Implementation Method 2
The RNAi pathway is initiated by the enzyme Dicer, which cleaves double-stranded RNA (dsRNA) molecules into short fragments... After integration into the RISC, the guide strand base-pairs with its target mRNA and is thought to either inhibit a target by inhibiting translation (by stalling the translational machinery) and/or inducing cleavage of the mRNA
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 2
AI summary
This invention is directed to a RNA interference (RNAi) agent and the use of that RNAi agent to treat hepatitis B infection in individuals, as well as pharmaceutical compositions containing the RNAi agents of the invention. The RNAi agents, or constructs for expressing them are utilised to inhibit expression of at least one Hepatitis B virus (HBV) gene, where the agent comprises an effector sequence complementary to or substantially complementary to a predicted sequence transcribed from a target region. In some forms of the invention, the agent has more than one effector sequence. Multiple effectors may target the same region of an HBV gene, different (possibly overlapping) regions of the same gene and/or different HBV genes.